209 related articles for article (PubMed ID: 37884625)
1. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C; Abbar B; Boussouar S; Bretagne M; Power JR; Moslehi JJ; Gougis P; Amelin D; Dechartres A; Lehmann LH; Courand PY; Cautela J; Alexandre J; Procureur A; Rozes A; Leonard-Louis S; Qin J; ; Cheynier R; Charmeteau-De Muylder B; Redheuil A; Tubach F; Cadranel J; Milon A; Ederhy S; Similowski T; Johnson DB; Pizzo I; Catalan T; Benveniste O; Hayek SS; Allenbach Y; Rosenzwajg M; Dolladille C; Salem JE
Nat Med; 2023 Dec; 29(12):3100-3110. PubMed ID: 37884625
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
4. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
Salem JE; Bretagne M; Abbar B; Leonard-Louis S; Ederhy S; Redheuil A; Boussouar S; Nguyen LS; Procureur A; Stein F; Fenioux C; Devos P; Gougis P; Dres M; Demoule A; Psimaras D; Lenglet T; Maisonobe T; De Chambrun MP; Hekimian G; Straus C; Gonzalez-Bermejo J; Klatzmann D; Rigolet A; Guillaume-Jugnot P; Champtiaux N; Benveniste O; Weiss N; Saheb S; Rouvier P; Plu I; Gandjbakhch E; Kerneis M; Hammoudi N; Zahr N; Llontop C; Morelot-Panzini C; Lehmann L; Qin J; Moslehi JJ; Rosenzwajg M; Similowski T; Allenbach Y
Cancer Discov; 2023 May; 13(5):1100-1115. PubMed ID: 36815259
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
Allenbach Y; Anquetil C; Manouchehri A; Benveniste O; Lambotte O; Lebrun-Vignes B; Spano JP; Ederhy S; Klatzmann D; Rosenzwajg M; Fautrel B; Cadranel J; Johnson DB; Moslehi JJ; Salem JE
Autoimmun Rev; 2020 Aug; 19(8):102586. PubMed ID: 32535094
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
7. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective.
Gougis P; Jochum F; Abbar B; Dumas E; Bihan K; Lebrun-Vignes B; Moslehi J; Spano JP; Laas E; Hotton J; Reyal F; Hamy AS; Salem JE
EClinicalMedicine; 2024 Apr; 70():102536. PubMed ID: 38560659
[TBL] [Abstract][Full Text] [Related]
8. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
[TBL] [Abstract][Full Text] [Related]
12. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice.
Tang X; Li Y; Huang H; Shi R; Shen LT; Qian WL; Yang ZG
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8345-8357. PubMed ID: 37076643
[TBL] [Abstract][Full Text] [Related]
13. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
14. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
15. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
[TBL] [Abstract][Full Text] [Related]
17. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
[TBL] [Abstract][Full Text] [Related]
19. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
[TBL] [Abstract][Full Text] [Related]
20. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]